CABA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cabaletta Bio Inc (CABA) is not a strong buy for a beginner investor with a long-term strategy at this time. While the company shows some positive developments, such as progress in its FDA-aligned registrational trial and improved net income, the lack of strong technical signals, neutral trading sentiment, and declining cash position suggest a cautious approach. The stock may be worth monitoring for future updates, but it does not currently present a compelling long-term investment opportunity.
The MACD is below 0 and negatively contracting, indicating a bearish trend. RSI is neutral at 38.876, and moving averages are converging, showing no clear momentum. The stock is trading near its pivot level of 2.953, with support at 2.709 and resistance at 3.198.
Guggenheim raised the price target to $16, citing robust efficacy data and clinical execution.
The FDA-aligned registrational trial is on track for a potential BLA submission in
Improved net income by 28.64% YoY in Q4 2025.
Cash position declined to $133.6 million, only supporting operations into Q4
EPS dropped by -36.51% YoY.
Morgan Stanley lowered the price target twice in recent months, reflecting cautious optimism.
In Q4 2025, the company reported a net income improvement of 28.64% YoY but still posted a loss of -$41.92 million. EPS decreased by -36.51% YoY to -$0.40. The cash position has declined, raising concerns about long-term sustainability.
Analysts are cautiously optimistic. Guggenheim raised the price target to $16, while Morgan Stanley lowered it to $13, citing ongoing progress but also reflecting concerns about the company's financials and execution risks.
